KeyBanc upgraded Cryoport (CYRX) to Overweight from Sector Weight with a $15 price target following the Q2 beat. The firm believes the cell and gene therapy market is gaining momentum as FDA approved therapies, particularly CAR-Ts, emerge as a significant growth driver. The analyst now has visibility into more consistent results going forward for Cryoport.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: